最新消息 生華科新藥臨床成果獲選ESMO發表 臨床數據PI 振奮值得期待 Jul 12 2024 最新消息 生華科新藥獲選美知名兒癌聯盟實驗藥 將爭取PRV加速上市 Jul 11 2024 最新消息 生華科延攬前嬌生亞太專家任醫務長 借重長才接軌國際 May 13 2024 媒體報導 生華科狙殺多達8種癌症兩新藥 首進美國癌症研究協會年會找商機 Apr 03 2024 媒體報導 疫情升溫 生華科料將加速收案 Dec 26 2023 媒體報導 生華科(6492)新冠藥Silmitasertib(CX-4945)創新布局染疫後免疫及蹦領域完成首位病人收案 Nov 09 2023 期刊 Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 期刊 Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 期刊 Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. Jan 12 2021